Evidence map›Paper›PMID 35800433›Full record

ArticleFrontiers in endocrinology2022

Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome.

Eli Muchtar, Matthew T Drake, Nelson Leung, Angela Dispenzieri, Martha Q Lacy, Francis K Buadi, David Dingli, Suzanne R Hayman, Prashant Kapoor, Yi Lisa Hwa and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Eli MuchtarDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Matthew T DrakeDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Nelson LeungDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Martha Q LacyDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Francis K BuadiDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
David DingliDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Suzanne R HaymanDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Prashant KapoorDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Yi Lisa HwaDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Amie FonderDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Miriam HobbsDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Wilson GonsalvesDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Taxiarchis V KourelisDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Stephen RussellDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Ronald S GoDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Moritz BinderDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Robert A KyleDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
S Vincent RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Shaji K KumarDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Morie A GertzDivision of Hematology, Mayo Clinic, Rochester, MN, United States.
Mayo Clinic · USWinnMed · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7M
NCI NIH HHS K12 CA090628NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Introduction: Vitamin D deficiency is common, but no data have been reported on vitamin D levels in light chain (AL) amyloidosis. Patients and Methods: In this exploratory study, stored serum samples from 173 patients with newly diagnosed AL amyloidosis were analyzed for vitamin studies which included 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH) Results: Cardiac and kidney involvement occurred in 69% and 63% of patients, respectively. 25(OH)D deficiency (<20 ng/mL) was seen in 56.6% of the patients and was notably found among patients with heavy proteinuria (96%), hypoalbuminemia (84.3%) and morbidly obese patients (68.3%). Heavy proteinuria (>5 gr/24-h) and vitamin D supplementation were independent predictors of 25(OH)D level on nominal multivariate regression analysis. 1,25(0H) Conclusions: Hypovitaminosis D is common in AL amyloidosis, particularly among patients with heavy proteinuria. Severe 25(OH)D deficiency at time of diagnosis predicts progression to ESRD.

Indexed as

HypoalbuminemiaImmunoglobulin Light-chain AmyloidosisKidney Failure, ChronicObesity, MorbidRenal InsufficiencyRicketsVitamin D DeficiencyHumansKidneyProteinuriaVitamin DVitaminsVitamin DVitaminsdialysiskidney survivalnephrotic syndromeproteinuriavitamin D

Identifiers

PMID35800433
PMCPMC9253369
OpenAlexW4283204705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.